<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37491104</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Improving resource utilisation in SLE drug development through innovative trial design.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000890</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000890</ELocationID><Abstract><AbstractText>SLE is a complex autoimmune disease with considerable unmet need. Numerous clinical trials designed to investigate novel therapies are actively enrolling patients straining limited resources and creating inefficiencies that increase enrolment challenges. This has motivated investigators developing novel drugs and treatment strategies to consider innovative trial designs that aim to improve the efficiency of generating evidence; these strategies propose conducting fewer trials, involving smaller numbers of patients, while maintaining scientific rigour in safety and efficacy data collection and analysis. In this review we present the design of two innovative phase IIb studies investigating efavaleukin alfa and rozibafusp alfa for the treatment of SLE which use an adaptive study design. This design was selected as a case study, investigating efavaleukin alfa, in the Food and Drug Administration's Complex Innovative Trial Design Pilot Program. The adaptive design approach includes prospectively planned modifications at predefined interim timepoints. Interim assessments of futility allow for a trial to end early when the investigational therapy is unlikely to provide meaningful treatment benefits to patients, which can release eligible patients to participate in other-potentially more promising-trials, or seek alternative treatments. Response-adaptive randomisation allows randomisation ratios to change based on accumulating data, in favour of the more efficacious dose arm(s), while the study is ongoing. Throughout the trial the placebo arm allocation ratio is maintained constant. These design elements can improve the statistical power in the estimation of treatment effect and increase the amount of safety and efficacy data collected for the optimal dose(s). Furthermore, these trials can provide the required evidence to potentially serve as one of two confirmatory trials needed for regulatory approval. This can reduce the need for multiple phase III trials, the total patient requirements, person-exposure risk, and ultimately the time and cost of investigational drug development programmes.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garces</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6601-5155</Identifier><AffiliationInfo><Affiliation>Amgen Inc, Thousand Oaks, California, USA sgarces@amgen.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karis</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Amgen Inc, Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merrill</LastName><ForeName>Joan T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askanase</LastName><ForeName>Anca D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0003-4597-5023</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Columbia University Irving Medical Center, New York (City), New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalunian</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy and Immunology, University of California San Diego School of Medicine, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>May</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Amgen Inc, Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milmont</LastName><ForeName>Cassandra E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Amgen Inc, Thousand Oaks, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04058028</AccessionNumber><AccessionNumber>NCT04680637</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adaptive Clinical Trial Design</Keyword><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword></KeywordList><CoiStatement>Competing interests: SG, EK, MM, CEM are employees and stockholders of Amgen. JTM is a consultant for AbbVie, Alexion, Amgen, AstraZeneca, Aurinia Pharmaceuticals, BMS, EMD Serono, Gilead, Genentech, GSK, Lilly, Merck, Pfizer, Provention Bio, RemeGen, Sanofi, UCB, and Zenas, is a speaker for AbbVie, Biogen, Sanofi, and RemeGen, and has received grants (to institution) from AstraZeneca, BMS, and GSK. ADA is an investigator and consultant for AbbVie, Amgen, AstraZeneca, Aurinia Pharmaceuticals, BMS, Celgene, Idorsia, Genentech, GSK, Janssen, Lilly, Mallinckrodt Pharmaceuticals, Pfizer, and UCB. KK is a consultant for AbbVie, AstraZeneca, Biogen, BMS, Cabaletta Bio, EMD Serono, Equillium, Genentech, Gilead, GSK, Kangpu Biopharmaceuticals, Kezar Life Sciences, Kyowa Kirin Co., and Merck, and has received research support from Acceleron Pharma, Alexion, Alpine Immune Sciences, Amgen, Horizon, Idorsia, Kyowa Kirin Co., Lupus Research Alliance and the Wolfe Family Program in Lupus, NIH, Novartis, Provention Bio, UCB, and Vera Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37491104</ArticleId><ArticleId IdType="pmc">PMC10373732</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000890</ArticleId><ArticleId IdType="pii">10/2/e000890</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lerang K, Gilboe I-M, Steinar Thelle D, et al. . Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study. Lupus 2014;23:1546&#x2013;52. 10.1177/0961203314551083</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314551083</ArticleId><ArticleId IdType="pubmed">25209070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014;384:1878&#x2013;88. 10.1016/S0140-6736(14)60128-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60128-8</ArticleId><ArticleId IdType="pubmed">24881804</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesinska M, Saletra A. Quality of life in systemic lupus erythematosus and its measurement. Reumatologia 2018;56:45&#x2013;54. 10.5114/reum.2018.74750</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2018.74750</ArticleId><ArticleId IdType="pmc">PMC5911658</ArticleId><ArticleId IdType="pubmed">29686443</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393:2344&#x2013;58. 10.1016/S0140-6736(19)30546-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol 2015;11:616&#x2013;20. 10.1038/nrrheum.2015.86</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.86</ArticleId><ArticleId IdType="pubmed">26122951</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918&#x2013;30. 10.1002/art.30613</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, et al. . Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211&#x2013;21. 10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ. Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience. Lupus 2016;25:1141&#x2013;9. 10.1177/0961203316652490</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316652490</ArticleId><ArticleId IdType="pubmed">27497258</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med 2017;4:e000239. 10.1136/lupus-2017-000239</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000239</ArticleId><ArticleId IdType="pmc">PMC5761306</ArticleId><ArticleId IdType="pubmed">29344386</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT. Problems remain in lupus clinical trial design. 2020. Available: https://www.healio.com/news/rheumatology/20200912/problems-remain-in-lupus-clinical-trial-design [Accessed 5 Dec 2022].</Citation></Reference><Reference><Citation>Medina-Qui&#xf1;ones CV, Ramos-Merino L, Ruiz-Sada P, et al. . Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken) 2016;68:981&#x2013;7. 10.1002/acr.22774</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22774</ArticleId><ArticleId IdType="pubmed">26554745</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. Ther Adv Musculoskelet Dis 2019;11:1759720X19874309. 10.1177/1759720X19874309</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X19874309</ArticleId><ArticleId IdType="pmc">PMC6755633</ArticleId><ArticleId IdType="pubmed">31565077</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Manzi S, Aranow C, et al. . Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med 2018;5:e000258. 10.1136/lupus-2018-000258</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000258</ArticleId><ArticleId IdType="pmc">PMC5894527</ArticleId><ArticleId IdType="pubmed">29657738</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakshi J, Segura BT, Wincup C, et al. . Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus. Clin Rev Allergy Immunol 2018;55:352&#x2013;67. 10.1007/s12016-017-8640-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-017-8640-5</ArticleId><ArticleId IdType="pmc">PMC6244922</ArticleId><ArticleId IdType="pubmed">28853005</ArticleId></ArticleIdList></Reference><Reference><Citation>Klavdianou K, Lazarini A, Fanouriakis A. Targeted biologic therapy for systemic lupus erythematosus: emerging pathways and drug pipeline. BioDrugs 2020;34:133&#x2013;47. 10.1007/s40259-020-00405-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-020-00405-2</ArticleId><ArticleId IdType="pubmed">32002918</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen ME, Rus V, Szeto GL. Leveraging heterogeneity in systemic lupus erythematosus for new therapies. Trends Mol Med 2021;27:152&#x2013;71. 10.1016/j.molmed.2020.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2020.09.009</ArticleId><ArticleId IdType="pmc">PMC8667782</ArticleId><ArticleId IdType="pubmed">33046407</ArticleId></ArticleIdList></Reference><Reference><Citation>Liossis SN, Staveri C. What&#x2019;s new in the treatment of systemic lupus erythematosus. Front Med 2021;8:655100. 10.3389/fmed.2021.655100</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.655100</ArticleId><ArticleId IdType="pmc">PMC7973110</ArticleId><ArticleId IdType="pubmed">33748165</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA guidance for industry systemic lupus erythematosus &#x2014; developing medical products for treatment_2010. 2010. Available: https://www.fda.gov/media/71150/download [Accessed 5 Dec 2022].</Citation></Reference><Reference><Citation>Dyball S, Collinson S, Sutton E, et al. . Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). Lupus Sci Med 2021;8:e000513. 10.1136/lupus-2021-000513</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000513</ArticleId><ArticleId IdType="pmc">PMC8311338</ArticleId><ArticleId IdType="pubmed">34301852</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M, Bruce IN, Gordon C, et al. . Current challenges in the development of new treatments for lupus. Ann Rheum Dis 2019;78:729&#x2013;35. 10.1136/annrheumdis-2018-214530</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214530</ArticleId><ArticleId IdType="pubmed">30636212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalunian KC, Kim M, Xie X, et al. . Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative. Eur J Rheumatol 2016;3:13&#x2013;9. 10.5152/eurjrheum.2015.0048</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2015.0048</ArticleId><ArticleId IdType="pmc">PMC5042268</ArticleId><ArticleId IdType="pubmed">27708963</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Pint&#xf3; I, Espinosa G, Cervera R. The problems and pitfalls in systemic lupus erythematosus drug discovery. Expert Opin Drug Discov 2016;11:525&#x2013;7. 10.1080/17460441.2016.1181056</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2016.1181056</ArticleId><ArticleId IdType="pubmed">27100941</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang M, Balser J. Adaptive design &#x2013; recent advancement in clinical trials. J Bioanal Biostat;2016;1:14. 10.13188/2641-8681.1000003</Citation><ArticleIdList><ArticleId IdType="doi">10.13188/2641-8681.1000003</ArticleId></ArticleIdList></Reference><Reference><Citation>Conduct of clinical trials of medical products during the COVID-19 public health emergency. 2022. Available: https://www.fda.gov/media/136238/download [Accessed 5 Dec 2022].</Citation></Reference><Reference><Citation>Rubin R. Clinical trials disrupted during war in Ukraine. JAMA 2022;327:1535-6. 10.1001/jama.2022.5571</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.5571</ArticleId><ArticleId IdType="pubmed">35385046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, Gordon C, Merrill JT, et al. . Clinical trials in lupus: what have we learned so far? Rheumatology (Oxford) 2010;49:1025&#x2013;7. 10.1093/rheumatology/kep462</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep462</ArticleId><ArticleId IdType="pubmed">20123955</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther 2015;17:183. 10.1186/s13075-015-0702-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0702-6</ArticleId><ArticleId IdType="pmc">PMC4507322</ArticleId><ArticleId IdType="pubmed">26189728</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA guidance document: adaptive design clinical trials for drugs and biologics guidance for industry, 2019. 2019. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry [Accessed 5 Dec 2022].</Citation></Reference><Reference><Citation>Pallmann P, Bedding AW, Choodari-Oskooei B, et al. . Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med 2018;16:29. 10.1186/s12916-018-1017-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-018-1017-7</ArticleId><ArticleId IdType="pmc">PMC5830330</ArticleId><ArticleId IdType="pubmed">29490655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bothwell LE, Kesselheim AS. The real-world ethics of adaptive-design clinical trials. Hastings Cent Rep 2017;47:27&#x2013;37. 10.1002/hast.783</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hast.783</ArticleId><ArticleId IdType="pubmed">29171051</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahlich J, Bartol A, Dheban S. Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis. Health Econ Rev 2021;11:4. 10.1186/s13561-021-00302-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13561-021-00302-6</ArticleId><ArticleId IdType="pmc">PMC7811738</ArticleId><ArticleId IdType="pubmed">33454837</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency . Adaptive pathways. Available: https://www.ema.europa.eu/en/human-regulatory/research-development/adaptive-pathways [Accessed 5 Dec 2022].</Citation></Reference><Reference><Citation>Complex innovative trial designs pilot program. 2022. Available: https://www.fda.gov/drugs/development-resources/complex-innovative-trial-designs-pilot-program [Accessed 5 Dec 2022].</Citation></Reference><Reference><Citation>Grayling MJ, Bigirumurame T, Cherlin S, et al. . Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential. BMC Rheumatol 2021;5:21. 10.1186/s41927-021-00192-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-021-00192-5</ArticleId><ArticleId IdType="pmc">PMC8252241</ArticleId><ArticleId IdType="pubmed">34210348</ArticleId></ArticleIdList></Reference><Reference><Citation>Winthrop KL, Isaacs JD, Mease PJ, et al. . Unmet need in rheumatology: reports from the Advances in Targeted Therapies Meeting, 2022 [published online ahead of print]. Ann Rheum Dis 2023;82:594&#x2013;8. 10.1136/ard-2022-223528</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-223528</ArticleId><ArticleId IdType="pubmed">36702529</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickles T, Alten R, Boers M, et al. . Adaptive trial designs in rheumatology: report from the OMERACT Special Interest Group. J Rheumatol 2019;46:1406&#x2013;8. 10.3899/jrheum.181054</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.181054</ArticleId><ArticleId IdType="pubmed">30770514</ArticleId></ArticleIdList></Reference><Reference><Citation>Complex Innovative Trial Design Meeting Program . Lupus Case Study. 2022. Available: https://www.fda.gov/drugs/development-resources/complex-innovative-trial-design-meeting-program#case%20studies [Accessed 5 Dec 2022].</Citation></Reference><Reference><Citation>Zhou L, Wang H, Jiang T, et al. . Design of an adaptive, phase 2, placebo-controlled, dose-ranging study to assess the efficacy and safety of AMG 570 in subjects with active SLE and inadequate response to standard of care therapy. Lupus Sci Med 2020;7(Suppl 1):A1&#x2013;131. 10.1136/lupus-2020-eurolupus.176</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-eurolupus.176</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchao N, Sarkar N, Hu X, et al. . EFAVALEUKIN alfa, a novel IL-2 mutein, selectively expands regulatory T cells in patients with SLE: final results of a phase 1b multiple ascending dose study. Ann Rheum Dis 2022;81(Suppl 1):1343. 10.1136/annrheumdis-2022-eular.2244</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.2244</ArticleId></ArticleIdList></Reference><Reference><Citation>Luijten KMAC, Tekstra J, Bijlsma JWJ, et al. . The Systemic Lupus Erythematosus Responder Index (SRI): A new SLE disease activity assessment. Autoimmun Rev 2012;11:326&#x2013;9. 10.1016/j.autrev.2011.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.06.011</ArticleId><ArticleId IdType="pubmed">21958603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, Lin L-A, Sankoh S. A general overview of adaptive randomization design for clinical trials. J Biom Biostat;2016;7:2. 10.4172/2155-6180.1000294</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2155-6180.1000294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ursino M, Stallard N. Bayesian approaches for confirmatory trials in rare diseases: opportunities and challenges. Int J Environ Res Public Health 2021;18:1022. 10.3390/ijerph18031022</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18031022</ArticleId><ArticleId IdType="pmc">PMC7908592</ArticleId><ArticleId IdType="pubmed">33498915</ArticleId></ArticleIdList></Reference><Reference><Citation>The Adaptive Platform Trials Coalition . Adaptive platform trials coalition: definition, design, conduct and reporting considerations. Nat Rev Drug Discov 2019;18:797&#x2013;807. 10.1038/s41573-019-0034-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0034-3</ArticleId><ArticleId IdType="pubmed">31462747</ArticleId></ArticleIdList></Reference><Reference><Citation>Elman SA, Ware JH, Gottlieb AB, et al. . Adaptive clinical trial design: an overview and potential applications in dermatology. J Invest Dermatol 2016;136:1325&#x2013;9. 10.1016/j.jid.2016.02.807</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jid.2016.02.807</ArticleId><ArticleId IdType="pubmed">27157773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lew RA, Liang MH, Doros G. Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier. Arthritis Res Ther 2015;17:345. 10.1186/s13075-015-0874-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0874-0</ArticleId><ArticleId IdType="pmc">PMC4669672</ArticleId><ArticleId IdType="pubmed">26634344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Popa S, Spindler AJ, et al. . Improvement of disease activity and reduction of severe flares following subcutaneous administration of an IL-6 monoclonal antibody (mAb) in subjects with active generalized systemic lupus erythematosus (SLE). Abstract presented at the 2014 ACR/ARHP annual meeting; 14&#x2013;19 November 2014. Boston, MA, USA.</Citation></Reference><Reference><Citation>Wallace DJ, Kalunian K, Petri MA, et al. . Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183&#x2013;90. 10.1136/annrheumdis-2012-202760</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202760</ArticleId><ArticleId IdType="pmc">PMC3888603</ArticleId><ArticleId IdType="pubmed">23313811</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Bruce IN, D&#xf6;rner T, et al. . Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:5397&#x2013;407. 10.1093/rheumatology/keab381</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab381</ArticleId><ArticleId IdType="pmc">PMC9194804</ArticleId><ArticleId IdType="pubmed">33956056</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahieu MA, Strand V, Simon LS, et al. . A critical review of clinical trials in systemic lupus erythematosus. Lupus 2016;25:1122&#x2013;40. 10.1177/0961203316652492</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316652492</ArticleId><ArticleId IdType="pmc">PMC4978143</ArticleId><ArticleId IdType="pubmed">27497257</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton VR, Suarez-Fueyo A, Meidan E, et al. . Pathogenesis of human systemic lupus erythematosus: A cellular perspective. Trends Mol Med 2017;23:615&#x2013;35. 10.1016/j.molmed.2017.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2017.05.006</ArticleId><ArticleId IdType="pmc">PMC5650102</ArticleId><ArticleId IdType="pubmed">28623084</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA impact story: using innovative statistical approaches to provide the most reliable treatment outcomes information to patients and clinicians. 2019. Available: https://www.fda.gov/drugs/regulatory-science-action/impact-story-using-innovative-statistical-approaches-provide-most-reliable-treatment-outcomes [Accessed 5 Dec 2022].</Citation></Reference><Reference><Citation>Berry SM, Broglio KR, Groshen S, et al. . Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials. Clin Trials 2013;10:720&#x2013;34. 10.1177/1740774513497539</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774513497539</ArticleId><ArticleId IdType="pmc">PMC4319656</ArticleId><ArticleId IdType="pubmed">23983156</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>